NCT06688123View on ClinicalTrials.gov

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

PHASE2RecruitingINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 30, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

SHR-3167

Dose level 1.

DRUG

SHR-3167

Dose level 2.

DRUG

Insulin glargine

Dose level 3.

Trial Locations (2)

200233

RECRUITING

Shanghai Sixth People's Hospital, Shanghai

210029

RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY